Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice

Polymer-drug conjugates: Recent development in clinical oncology

“…PG-CPT conjugate was obtained by directly coupling the hydroxy group at the C20(S)-position of CPT with the carboxylic acid of PG [65]. When given intravenously in four doses every 4 days at an equivalent CPT of 40 mg/kg, PG-CPT delayed the growth of established H322 human lung tumors grown subcutaneously in nude mice.…”

Antitumor Activity of Hydrophilic Paclitaxel Copolymer Prodrug Using Locoregional Delivery in Human Orthotopic Non–Small Cell Lung Cancer Xenograft Models

“…Another study of two compartmental models of intraperitoneal human ovarian carcinoma xenografts with locoregional (intraperitoneal) drug administration demonstrated the superior antitumor efficacy of even a single-dose administration of PGA-TXL compared with multiple-dose Taxol (28). Although PGA-TXL has not previously been evaluated in an orthotopic human lung cancer xenograft model, a PGA backbone copolymer of camptothecin (CPT) as been evaluated in a model similar to the ones used in the present study (34). Systemic (intravenous) administration of this CPT construct markedly improved the survival of the hosts bearing H322 intratracheal tumors, whereas these models were resistant to intravenous CPT or cisdiamminedichloroplatinum.…”

Renal targeting potential of a polymeric drug carrier, poly-L-glutamic acid, in normal and diabetic rats

“…At the same time, we also point out the possible compromise of renal reuptake or targeting of this class of carrier in a diseased kidney (for example, oxidative-stressed kidney in our study). Compared to using a small-sized renal targeting drug carrier, the feasibility of employing a drug carrier having a molecular size above the renal filtration threshold for renal targeting drug was not previously reported, although the renal accumulation of tumor-targeting drug carriers of such size range (for example, N- [2-hydroxypropyl] 52 and PG [27][28][29][30][31][32] ) has been described. In the current study, we have performed some assessments on the renal accumulation patterns of 41 kDa PG and we would like to propose 41 kDa PG as a renal drug carrier that is potentially capable of delivering drug payload to the renal tissues in both normal and compromised renal anatomical or physiological states (oxidative stress-induced kidney in the current study as an example).…”

“…[27][28][29] Studies on other PG-chemotherapeutic conjugates have shown similar findings. [30][31][32] These favorable observations led us to assess the potential use of PG polymers as a renal targeting carrier.…”